[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609676":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":35,"responsibleParty":53,"collaborators":56,"id":60,"slug":20,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":20,"eligibilityCriteria":64,"healthyVolunteers":61,"sex":65,"minAge":66,"maxAge":20,"enrollmentInfo":67,"targetDuration":20,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":20,"overallStatus":38,"whyStopped":20,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University of Miami","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Durysta","EXPERIMENTAL","Participants will receive a one-time intracameral administration of Durysta - bimatoprost 10mcg",[13],"Drug: Durysta, Bimatoprost Intracameral Implant 10 µg",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Durysta, Bimatoprost Intracameral Implant 10 µg","Participants in this arm will receive a one-time injection of Durysta (intracameral bimatoprost 10mcg). Participants will be followed by a total of 3 months.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Swarup S Swaminathan, MD","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Javier Paredes, BA, MBA","CONTACT","305-326-6387","jxp2537@med.miami.edu",{"name":32,"role":28,"phone":33,"phoneExt":20,"email":34},"Monica Arango, BA","305-326-6351","mrarango@med.miami.edu",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Bascom Palmer Eye Institute","RECRUITING","Miami","Florida","33134","United States",{"type":44,"coordinates":45},"Point",[46,47],-80.19366,25.77427,{"lat":47,"lon":46},[50,51,52],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"name":32,"role":28,"phone":33,"phoneExt":20,"email":34},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":24,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Swarup Swaminathan","Associate Professor of Ophthalmology",[57],{"name":58,"class":59},"AbbVie","INDUSTRY","100609676",false,"NCT07217678","Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use","Inclusion Criteria:\n\n* Eye with open-angle glaucoma or suspected of open-angle glaucoma\n* Pseudophakic in eye of interest with Shafer grading ≥3\n* ≤ 3 daily applications of topical glaucoma medications for ≥6 months (of which one is a nightly preserved PGA)\n* Good adherence to medication regimen - screening questions to be asked of potential subject:\n* In the last month, what percentage of the time would you estimate missing the application of drops? (Must be ≤20%)\n* When was the last administration? (Last dose must have been within last 24 hours)\n* Presence of punctate epithelial erosions in the cornea (NEI scale \\> 3)\n\nExclusion Criteria:\n\n* Retinal disease (e.g., wet age-related macular degeneration, proliferative diabetic retinopathy, central retinal vein occlusion)\n* Use of topical or systemic immunosuppressor or immunomodulator drug (e.g., steroids, cyclosporine, lifitegrast, or antihistamines)\n* Use of preservative-free hypotensive medications\n* Any clinical contraindications to receiving intracameral bimatoprost implantation\n* History of recurrent conjunctivitis (e.g., allergic or atopic conjunctivitis)\n* History of partial or full corneal transplant\n* History of ophthalmic surgery (intraocular or tarsus-involving oculoplastic procedures) within last 6 months\n* History of subconjunctival glaucoma surgery (i.e., trabeculectomy, aqueous shunt, Xen implant) within last 6 months","ALL","18 Years",{"count":68,"type":69},20,"ESTIMATED","INTERVENTIONAL",[72],"PHASE4","The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.",[75,76,77,78],"Glaucoma","Open-Angle Glaucoma","Ocular Hypertension","Glaucoma Suspect","2026-03-03",{"date":81,"type":82},"2026-03-05","ACTUAL",{"date":84,"type":82},"2026-02-09",{"date":86,"type":69},"2028-01-31",{"name":5,"class":6},1]